Anke Biotechnology: PA3-17 Injection has been approved for new indications in clinical trials.

Ankang Biological announced that the clinical trial application for the new indication of the PA3-17 injection developed independently by its affiliated companies Boshengji Medical Technology Co., Ltd. and Boshengji Ankang Cell Technology Co., Ltd. has been approved by the National Medical Products Administration. The approval allows for conducting clinical trials for the treatment of relapsed/refractory T-cell lymphoblastic leukemia/lymphoma in children and adolescents. The PA3-17 injection is the world's first autologous CAR-T cell therapy product targeting CD7 to receive approval for a new drug clinical trial. It has been included in the "Breakthrough Therapy" category and a pivotal Phase II clinical trial for adult patients is currently ongoing. This approval marks a milestone in the expansion of indications for the product, and if approved for marketing in the future, it will further expand the range of applicable populations.